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Activation of Serotonin 2A Receptors Underlies the
Psilocybin-Induced Effects on  Oscillations, N170
Visual-Evoked Potentials, and Visual Hallucinations
Michael Kometer,1 Andre´ Schmidt,1 Lutz Ja¨ncke,2 and Franz X. Vollenweider1
1Neuropsychopharmacology and Brain Imaging, Clinic of Affective Disorders and General Psychiatry, University Hospital of Psychiatry, University of
Zurich, Zurich 8008, Switzerland, and 2Department of Neuropsychology, University of Zurich, Zurich 8050, Switzerland
Visual illusions and hallucinations are hallmarks of serotonergic hallucinogen-induced altered states of consciousness. Although the
serotonergic hallucinogen psilocybin activates multiple serotonin (5-HT) receptors, recent evidence suggests that activation of 5-HT2A
receptors may lead to the formation of visual hallucinations by increasing cortical excitability and altering visual-evoked cortical re-
sponses. To address this hypothesis, we assessed the effects of psilocybin (215 g/kg vs placebo) on both  oscillations that regulate
cortical excitability and early visual-evoked P1 and N170 potentials in healthy human subjects. To further disentangle the specific
contributionsof 5-HT2Areceptors, subjectswereadditionallypretreatedwith thepreferential 5-HT2Areceptor antagonist ketanserin (50
mgvs placebo).We found that psilocybin strongly decreased prestimulus parieto-occipitalpower values, thus precluding a subsequent
stimulus-induced  power decrease. Furthermore, psilocybin strongly decreased N170 potentials associated with the appearance of
visual perceptual alterations, including visual hallucinations. All of these effects were blocked by pretreatment with the 5-HT2A antag-
onist ketanserin, indicating that activation of 5-HT2A receptors by psilocybin profoundly modulates the neurophysiological and phe-
nomenological indices of visual processing. Specifically, activation of 5-HT2A receptors may induce a processing mode in which
stimulus-driven cortical excitation is overwhelmed by spontaneous neuronal excitation through the modulation of  oscillations. Fur-
thermore, the observed reduction of N170 visual-evoked potentials may be a key mechanism underlying 5-HT2A receptor-mediated
visual hallucinations. This change inN170 potentialsmay be important not only for psilocybin-induced states but also for understanding
acute hallucinatory states seen in psychiatric disorders, such as schizophrenia and Parkinson’s disease.
Introduction
Recent evidence from molecular, pharmacological, and neuro-
imaging studies suggests a crucial role for serotonin 2A (5-HT2A)
receptors in visual processing and the pathogenesis of visual hal-
lucinations. 5-HT2A receptors are highly expressed in the visual
cortex (Gerstl et al., 2008; Watakabe et al., 2009; Moreau et al.,
2010) and alterations in their cortical density in both Parkinson’s
disease (Ballanger et al., 2010; Huot et al., 2010) and schizophre-
nia (Gonza´lez-Maeso et al., 2008) are associated with the appear-
ance of visual hallucinations. Furthermore, activation of 5-HT2A
receptors predominantly mediates the visual hallucinations that
are induced by serotonergic hallucinogens, such as psilocybin
and LSD (Nichols, 2004; Vollenweider and Kometer, 2010),
whereas the 5-HT2A receptor inverse agonist pimavanserin is
effective for treatment of visual hallucinations in Parkinson’s dis-
ease (Meltzer et al., 2010). However, despite the increasingly rec-
ognized significance of 5-HT2A receptors in visual perception,
the effects of 5-HT2A receptor activation on neurophysiological
mechanisms that underlie visual processing and hallucinations
remain largely unknown. Therefore, we assessed the effects of
5-HT2A receptor activation on the prestimulus oscillatory state
of the visual parieto-occipital network and the subsequent visual
stimulus-induced activity. Furthermore, we asked whether these
effects are related to the formation of visual hallucinations.
The first evidence to suggest that activation of 5-HT2A recep-
tors increases the excitability of the visual cortex in the absence of
externally presented visual stimuli came recently from animal
studies (Moreau et al., 2010). In addition, computational models
propose that increasing the excitability state of the visual cortex
may destabilize spontaneous network activity, which in turn
might produce elementary visual hallucinations (Ermentrout
and Cowan, 1979; Bressloff et al., 2002; Gutkin et al., 2003; Butler
et al., 2012). Parieto-occipital  oscillations are crucial for mod-
ulation of visual network excitability, and thereby strongly influ-
ence visual perception (Thut et al., 2006; Romei et al., 2008a;
Jensen and Mazaheri, 2010; Klimesch, 2011; Mathewson et al.,
2011) and visual-evoked potentials (Gruber et al., 2005; Kli-
mesch, 2011; Rajagovindan and Ding, 2011). Therefore, we hy-
pothesized that activating 5-HT2A receptors with psilocybinmay
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modulate  oscillations, which could lead to an altered excitabil-
ity that would promote the formation of visual hallucinations.
In addition, activation of 5-HT2A receptors may modulate
the visual cortex response to external stimuli that are indexed by
visual-evoked potentials. In support of this view, the unselective
5-HT2A receptor agonist psilocybin increases medial P1 visual-
evokedpotentials (Kometer et al., 2011), which reflect early visual
gain (Rajagovindan and Ding, 2011). Furthermore, psilocybin-
induced visual hallucinations are associated with decreased N1/
N170 potentials (Kometer et al., 2011) that underlie mid-level
visual organization processes (Herrmann and Bosch, 2001).
5-HT2A receptors likely mediate this psilocybin-induced de-
crease inN170 potentials because activation of 5-HT2A receptors
predominantly mediates psilocybin-induced visual hallucina-
tions (Vollenweider et al., 1998; Vollenweider and Kometer,
2010). However, psilocybin also activates 5-HT1A and 2C recep-
tors (Nichols, 2004), and 5-HT1A receptors are also expressed in
the visual cortex (Dyck and Cynader, 1993; Gerstl et al., 2008;
Watakabe et al., 2009). Therefore, the specific effects of 5-HT2A
receptors activation on visual-evoked potentials remain
unknown.
Materials andMethods
Subjects
Seventeen subjects were enrolled. All subjects were deemed healthy
through physical examinations, which included detailed blood analyses
and electrocardiography. The Mini-International Neuropsychiatric In-
terview, MINI-SCID (Sheehan et al., 1998), the DIA-X diagnostic expert
system (Wittchen and Pfister, 1997), and the Hopkins Symptom Check-
list SCL-90-R (Derogatis, 1994) were used to exclude subjects with pres-
ent or previous psychiatric disorders or a history of major psychiatric
disorders in first-degree relatives. Urine drug screens and self-report
drug use questionnaires were used to verify the absence of substance
dependence.
Subjects receivedwritten and oral descriptions of the study procedures
as well as the effects and possible risks of psilocybin administration.
Subjects provided written informed consent before participation in the
study. One of the 17 subjects was excluded for dizziness after the com-
bined administration of psilocybin and ketanserin. The data from an-
other subject were excluded from analyses because the majority of the
trials were contaminated by artifacts. A total of 15 subjects were included
in the statistical analyses (11 males, 4 females; mean age, 26.6  4.25
years).
Substance and dosing
A double-blind, placebo-controlled, within-subject, randomized design
was used. Each subject received on four different experimental days that
were separated by at least 2 weeks with four different drug combinations:
placebo and ketanserin (50 mg) (pretreatment) followed by placebo and
psilocybin (215 g/kg) (treatment) after 1 h. These specific doses were
chosen because they have previously been shown to induce and block the
associated changes in conscious states (Carter et al., 2005). The visual
stimulation experiments began 90min after treatment during the known
plateau of the peak subjective psilocybin effects (Studerus et al., 2011).
The self-report questionnaires were completed 360 min after treatment
to retrospectively rate the subjective experience after drug intake.
The Swiss Federal Office of Public Health, Department of Pharmacol-
ogy and Narcotics, Bern, Switzerland authorized the use of psilocybin in
humans. The ethics committee of the University Hospital of Psychiatry,
Zurich approved the study.
Self-report questionnaire
The Altered States of Consciousness (5D-ASC) questionnaire (Dittrich,
1998) was used to quantify the subjective psychological effects of drug
administration, with a primary focus placed on visual alterations and
hallucinations. The 5D-ASC is a visual analog scale of 94 items that
measure etiology-independent alterations in consciousness, including
changes in perception, mood, cognition, and experience of self and en-
vironment. The 5D-ASC comprises five main scales (Dittrich, 1998):
Visionary restructuralization, measuring visual illusions and both ele-
mentary and complex hallucinations; Oceanic boundlessness,measuring
derealization and depersonalization accompanied by an altered sense of
time and by positive mood states; Anxious ego dissolution, measuring
ego disintegration associated with loss of self-control, thought disorder,
arousal, and anxiety; Auditory alterations, comprising auditory illusions
and hallucinations; and Reduction of vigilance, measuring changes in
vigilance and alertness. In addition, 11 lower-order subscales were re-
cently extracted by confirmatory factor analysis (Studerus et al., 2010).
These were here used for a detailed exploratory analysis. The 11 subscales
are as follows: Elementary imagery, Complex imagery, Audio-visual syn-
estesiae, Experience of unity, Spiritual experience, Blissful state, Insight-
fulness, Changed meaning of percepts, Disembodiment, Impaired
control and cognition, and Anxiety.
For the purpose of the present study, subscales quantifying visual per-
ceptual alterations were of particular interest. These included the main
scale Visionary restructuralization and the 3 lower-order subscales: Ele-
mentary imagery, measuring visual hallucinations of regular patterns,
colors, or light flashes; Complex imagery, quantifying visual hallucina-
tions of scenes and pictures; and Audio-visual synesthesiae, measuring
visual perceptual alterations that are driven by acoustic noise or sound.
Stimulus and procedure
Subjects remained fixated on a central cross during visual stimulus pre-
sentations. All stimuli included three “pacman” figures, whichwere black
circles with a 60° section removed from each circle. The removed sectors
were either aligned to induce the perception of an illusory triangle
(“Kanizsa” condition) or rotated 180° to an alignment that no longer
induced the illusory triangle perception (“non-Kanizsa” condition)
(Kometer et al., 2011). The visual angle of the stimuli was 5.4° instead of
the previously described 3.7° (Kometer et al., 2011) because increases in
eccentricity induce higher P1 amplitudes (Murray et al., 2002; Busch et
al., 2004). To reduce habituation, the stimuli were randomly presented in
four orientations: rotated 0°, 90°, 180°, and 270°. In total, 88 Kanizsa
figures and 88 non-Kanizsa figureswere presented in a randomized order
with a 3 s stimulus onset asynchrony. Participants responded by pressing
a button as quickly as possible when they perceived an illusory triangle.
Stimuli remained on the monitor for 300 ms after a button press or for a
maximum of 2000 ms.
EEG recording
Continuous electroencephalograms (EEGs) were acquired from 64
Ag-AgCl electrodes using the BioSemi ActiveTwo electrode system
(BioSemi). Additional electrodes were attached to the outer canthus of
each eye and both infraorbitally and supraorbitally to the left eye to
record the horizontal and vertical electroocculograms, respectively. Elec-
trophysiological signals were bandpass filtered online between 0.01 and
67 Hz and digitized with a sampling rate of 512 Hz.
EEG analysis
Preprocessing. The EEG data were recalculated offline against the com-
mon average reference, and bad channels (2%)were interpolated using
spherical splines (Perrin et al., 1989). EEG data were epoched from 800
ms before to 600 ms after stimulus onset. To avoid eye movements,
periods of high muscle activity, and other noise transients, an automatic
artifact rejection excluded epochs in which voltage values of the raw
unfiltered data exceeded  120 V in four or more electrodes. The
remaining epochs were screened manually to reject epochs with residual
eye movement artifacts.
Time-frequency analysis. To calculate phase and power at 1 Hz
frequency steps between 4 and 100 Hz, signals x(t) from each
trial were convolved with a family of Morlet wavelets, wt, fo) 
A exp( t2/2t
2)exp(2ifot), where fo is the central frequency, t is the
time, and i is the imaginary part i   1.Wavelets were normalized
using the factor A(w) (t )1/ 2. The family ratio, m fo/f 5,
was used, where f is the width of the Gaussian shape in the frequency
domain. This ratio was used to optimize the trade-off between the tem-
poral and frequency resolutions of the wavelet convolution.
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The power for each trial was computed as the sum of the squares of the
real and the imaginary Morlet wavelet components, which was subse-
quently averaged over single trials separately for all conditions. To quan-
tify stimulus-induced activity (e.g., the change of power that is induced
by the presentation of the visual stimulus), poststimulus power values
were baseline-corrected by subtracting the mean power observed during
the 400 to 200 ms prestimulus interval (Snyder and Foxe, 2010;
Banerjee et al., 2011; Scheeringa et al., 2011; Waldhauser et al., 2012).
The extent of normalized phase variability across trials for each con-
dition was quantified using the phase-locking value (also called intertrial
coherence or phase-locking factor) at each time point, t, and frequency,
fo. This procedure yielded a phase-locking value measure that ranged
from 0 to 1. A value of 0 indicated completely randomized phases across
different trials at a specific time point, t, and a value of 1 indicated a
consistent phase across trials.
Event-related potential (ERP) analysis. After bandpass filtering (0.5–40
Hz) of the preprocessed data (see above), ERPs were computed by aver-
aging separately all trials for each condition and subject. Subsequently,
the P1 and N170 amplitudes were quantified against the 200 ms baseline
as the mean amplitudes observed during a 40 ms time frame that was
centered on the time point corresponding to the peak maximum. This
resulted in a time frame from 80 to 120ms for the P1 and 150–190ms for
the N170 amplitudes.
Statistical analysis
Three parieto-occipital ROIs were selected for the statistical analyses of
ERPs,  power, and phase values. These three ROIs included the follow-
ing electrodes: parietal left (P3, P5, P7, PO3, PO7), parietal medial (POz,
Oz, O1, O2, Iz), and parietal right (P4, P6, P8, PO4, PO8). These ROIs
have previously been used to quantify  power and phase values (Zanto
et al., 2011) and covered the maximal P1 and N170 amplitudes in the
current study.
Only the time frame between600 and 400 ms was considered in the
analyses of power and phase values to ensure that edge effects did not
contaminate the statistical analyses (Cohen et al., 2007). Prestimulus 
(8–12 Hz) power was collapsed over the600 to200 ms time frame.
Stimulus-induced  power was collapsed into two time frames (0–200
ms and 200–400ms) because visual inspection of the data indicated that
there was a stimulus-induced increase during the first time frame (0–200
ms), but a stimulus-induced decrease during the second time frame
(200–400 ms).
All dependent variables were subjected to repeated-measures ANOVA
(specific factors are defined in Results), and the Greenhouse-Geisser cor-
rection was applied. Bonferroni-corrected post hoc comparisons were
performed based on significant main effects and interactions. Pearson’s
product moment correlations were computed to assess hypothesis-
driven relationships between physiological parameters and self-reported
visual perceptual alterations. First, the relationship between psilocybin-
induced decreases of N170 potentials and perceptual alterations was rep-
licated (Kometer et al., 2011) and specified. Second, whether increased
excitability that is indexed by decreased  oscillations (Thut et al., 2006;
Romei et al., 2008a; Jensen and Mazaheri, 2010; Klimesch, 2011;
Mathewson et al., 2011) resulted in elementary hallucinations (Ermen-
trout andCowan, 1979; Bressloff et al., 2002; Gutkin et al., 2003; Butler et
al., 2012) was tested by correlating  power values with the elementary
hallucination subscale of the 5D-ASC. Finally, psilocybin-induced
changes in prestimulus  power values were correlated with the
psilocybin-induced changes in P1 potentials because prestimulus 
power values are closely associated with P1 potentials (Klimesch, 2011;
Rajagovindan and Ding, 2011).
Results
Behavioral data
Psychometrics
A repeated-measures ANOVA on the three primary dimensions
of the 5D-ASC rating scale using pretreatment, treatment, and
dimensions as within factors revealed a main effect of treatment
(F(1,14) 75.85, p 0.000001) and a treatment pretreatment
interaction (F(1,14) 85.05, p 0.000001). Bonferroni-corrected
post hoc analyses of this interaction indicated that treatment with
psilocybin generally increased 5D-ASC scores when adminis-
tered after placebo pretreatment (p  0.0000001), but not after
ketanserin pretreatment (p 1). The triple interaction between
pretreatment treatment factor (F(2,28) 30.62, p 0.00001)
demonstrated a similar significant relationship for the Visionary
restructuralization scale. Bonferroni-corrected post hoc analysis
indicated that the strong psilocybin-induced increase in the Vi-
sionary restructuralization scores (p  0.0001) was absent after
ketanserin pretreatment (p  1). The scores of the recently
formed 11 subscales (seeMaterials andMethods) were submitted
to separate repeated-measures ANOVAs. The triple interaction
between treatment pretreatment factor (F(10,140) 9.44, p
0.00001) indicated that psilocybin robustly induced several visual
perceptual alterations after placebo pretreatment, including
complex visual hallucinations of scenes and pictures (p 
0.0000001), visual elementary hallucinations of regular patterns,
colors, light and light-flashes (p 0.0000001), and an alteration
of visual percepts by auditory stimuli (p 0.0001). However,
no subscales were altered after ketanserin pretreatment (all p
values  1).
Reaction times (RT) and error rates
Neither RTs for correct responses nor error rates were signifi-
cantly modulated by psilocybin treatment (RTs: F(1,14)  2.16,
p  0.16, error rates: F(1,14)  0.21, p  0.65) or ketanserin
pretreatment (RTs: F(1,14) 0.19, p 0.090, error rates: F(1,14)
3.73, p 0.074). Although an interaction between treatment and
stimulus (F(1,14)  5.124, p  0.05) indicated that psilocybin
increased the error rates for Kanizsa stimuli (p  0.05) but not
those for non-Kanizsa stimuli (p  1), the error rates remained
very low under all conditions (between 1.1% and 3.4%). There-
fore, we are confident that participants could do the task under all
drug conditions.
ERP analyses
P1
A repeated-measures ANOVA on P1 amplitudes (using pretreat-
ment, treatment, stimulus, and ROI as within factors) revealed a
significant interaction between treatment and ROI (F(2,28) 
8.15, p  0.01) and between pretreatment and ROI (F(2,28) 
19.88, p  0.0001). Post hoc analyses of these interactions
indicated that psilocybin treatment selectively increased P1
amplitudes over the medial (p  0.05), but not the lateral,
parieto-occipital ROIs. By contrast, P1 amplitudes over the
medial parieto-occipital ROI were selectively decreased by
ketanserin pretreatment (p  0.00001) (Figs. 1 and 2).
N170
A repeated-measures ANOVA on N170 amplitudes (using pre-
treatment, treatment, stimulus, and ROI as within factors) re-
vealed a significant main effect of treatment (F(1,14)  5.34, p 
0.05), which replicated a previous report of psilocybin-induced
decrease of N170 amplitudes (Kometer et al., 2011). In addition,
the significant interaction between treatment and pretreatment
(F(1,14)  7.55, p  0.05) and the subsequent Bonferroni-
corrected post hoc analyses indicated that psilocybin treatment
decreased the N170 component after placebo (p 0.01) but not
after ketanserin pretreatment (p 1) (Fig. 1). Correlation anal-
ysis with the original main five factors of the 5D-ASC revealed
that this psilocybin-induced N170 decrease correlated only with
the psilocybin-induced increase in Visionary restructuralization
(r 0.73, p 0.01), but not with Auditory alteration (r 0.37,
p  0.169), Oceanic boundlessness (r  0.40, p  0.135), Anx-
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ious ego dissolution (r  0.07, p  0.801), or the Reduction of
vigilance (r 0.35, p 0.203). Thus, the N170 decrease seems to
be selectively associated with visual perceptual alterations. In
support of this view, correlation analysis between the 11 newly
constructed lower-order subscales of the 5D-ASC scales and the
N170 decrease revealed that only the three subscales comprising
visual perceptual alterations were associated with the N170 de-
crease (Complex imagery, r 0.61, p 0.05; Elementary imag-
ery, r 0.49, p 0.067; Audiovisual synesthesiae, r 0.54, p
0.05) (Fig. 1).
Time-frequency analyses
Prestimulus  power
The  power values (8–12 Hz) observed during the prestimulus
time frame (600 to 200 ms) were subjected to a repeated-
measures ANOVA (using pretreatment, treatment, stimulus, and
ROI as within factors). A main effect of ROI (F(2,28) 3.66, p
0.05) indicated that the  power values were most pronounced
over the right parieto-occipital region. Psilocybin strongly de-
creased the prestimulus  power values (F(1,14)  10.05, p 
0.01). This decrease was dependent on the pretreatment condi-
tion (F(1,14) 8.55, p 0.05) as the psilocybin-induced decrease
in power values was significant after pretreatment with placebo
(p  0.01) but not ketanserin (p  1) (Fig. 3). Correlational
analyses revealed that the psilocybin-induced decrease in 
power values correlated significantly with the psilocybin-induced
increase in the medial P1 potential (r0.634, p 0.05).
Stimulus-induced  power
A repeated-measures ANOVA on the stimulus-induced  power
values (using pretreatment, treatment, stimulus, time, and ROI
as within factors) revealed a main effect of time (F(1,14) 32.80,
Figure 1. A, Effects of psilocybin and ketanserin on group-averaged event-related potential waveforms for the three parieto-occipital ROIs. Placebo placebo (black), placebo psilocybin
(red), ketanserin placebo (blue), and ketanserin psilocybin (green).B, Correlation between the psilocybin-induced reduction of N170 amplitudes and the psilocybin-induced perceptual visual
alterations as measured by the main scales (B1) and subscales (B2) of the 5D-ASC questionnaire.
Figure2. The scalp topographicmaps depict the difference between theplaceboplacebo
condition and the placebo psilocybin condition in the P1 amplitude (80 to 120 ms), in the
N170 amplitude (150 to 190ms) and in the prestimulus power values (600 to200ms).
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p 0.0001), indicating a decrease in power from baseline level,
during the 200–400 ms time frame (Fig. 3). The significant in-
teraction between time  treatment (F(1,14)  16.58, p  0.01)
revealed that this stimulus-induced  power decrease was re-
duced by psilocybin, particularly during the 200–400 ms time
frame (p 0.0000001). The three-way interaction between treat-
ment  pretreatment  time (F(1,14)  7.24, p  0.05) further
indicated that the reduction of stimulus-induced  power de-
creases by psilocybin during the 200–400 ms time frame was
reversed by ketanserin pretreatment, as the stimulus-induced de-
crease of  power was significantly higher in the ketanserin 
psilocybin condition than in the placebo psilocybin condition
(p 0.0001).
Relationship between prestimulus and stimulus-induced  power
Because prestimulus  power values were strongly reduced by
psilocybin administration, it is conceivable that this reduction
was responsible for the subsequent lack of stimulus-induced 
power decrease in the psilocybin condition. To test this hypoth-
esis, we restricted the analysis of the stimulus-induced power to
the small subsets of trials that had lowprestimuluspower values
equal to those in the placebo psilocybin condition. Thus, from
all pharmacological conditions, only trials with a prestimulus
power value between 0 and 0.5V2 were subjected to a repeated-
measures ANOVA using pretreatment, treatment, time, and ROI
as within factors. In contrast to the analysis, including all trials,
this analysis did not reveal a significant interaction between time
and treatment (F(1,14) 0.09, p 0.76) or between time treat-
ment pretreatment (F(1,14) 1.02, p 0.33), which indicates
that the lack of stimulus-induced  power decrease is a conse-
quence of the strong psilocybin-induced decrease in prestimulus
 power.
Phase-Locking Index (PLI)
A repeated-measures ANOVA (using pretreatment, treatment,
time, stimulus, and ROI as within factors) on the PLI revealed a
main effect of time (F(1,14) 30.74, p 0.0001), indicating par-
ticularly high PLI values during the 0–200 ms time frame. The
significant interaction between pretreatment and time (F(1,14)
37.60, p  0.0001) indicated that ketanserin pretreatment de-
creasedPLI during the 0–200ms time frame (p 0.0001) but not
during the 200–400 ms time frame (p  0.439). This decrease
was most pronounced over the medial parieto-occipital ROI
(p  0.0000001), followed by the left (p  0.001), and then the
right parieto-occipital ROIs (p  0.01; pretreatment  time 
ROI: F(2,28) 5.56, p 0.05) (Fig. 4).
Discussion
The data presented in the current study demonstrate that psilo-
cybin strongly decreased prestimulus  power values and, conse-
Figure 3. Effects of psilocybin treatment and ketanserin pretreatment on power values in three parieto-occipital ROIs.A, Time course for power values (8–12Hz) as a function of placebo
placebo (black), placebopsilocybin (red), ketanserinplacebo (blue), and ketanserinpsilocybin (green).B, Time course for the difference in power values betweenplacebopsilocybin and
placebo placebo for all frequencies (4–52 Hz).
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quently, precluded the subsequent stimulus-induced  power
decrease. Moreover, psilocybin decreased N170 visual-evoked
potentials that were associated with the appearance of visual hal-
lucinations. These psilocybin-induced effectswere normalized by
pretreatment with the 5-HT2A receptor antagonist ketanserin,
indicating that activation of 5-HT2A receptors is crucial for me-
diating these effects.
Alpha oscillations (8–12 Hz) have been identified as major
neural mechanisms that regulate the excitability levels of cortical
sensory networks through inhibition (Thut et al., 2006; Romei et
al., 2008b; Klimesch, 2011). In the current study, high parieto-
occipital  power levels were observed with placebo conditions
during the prestimulus time range, which suggests that a high
level of inhibition reduced the excitability of the visual network in
the absence of task-relevant visual inputs (Klimesch, 2011; Palva
and Palva, 2011). This high level of prestimulus  power was
strongly attenuated by psilocybin. Furthermore, this effect of psi-
locybin was in turn reversed by ketanserin pretreatment, suggest-
ing that activation of 5-HT2A receptors increases the excitability
of the visual network in the absence of externally presented stim-
uli by decreasing ongoing  oscillation. As a consequence of this
strong  power decrease during the prestimulus time-frame, the
generation of the subsequent stimulus-induced decrease in 
power was precluded, indicating a lack of a stimulus-induced
increase in excitability (Hanslmayr et al., 2009; Klimesch, 2011).
Thus, the high excitability levels in the absence of externally pre-
sented stimuli may have restricted the capacity of the visual sys-
tem to increase, by a modulation of  power, the excitability for
processing incoming stimuli.
Together, the results indicate that 5-HT2A receptor activation
induces primarily by attenuating ongoing  oscillation a dysbal-
ance between the excitability observed in the absence of an exter-
nal stimulus and the excitability that is induced by the
presentation of the stimulus. The dysbalance may reflect a shift
away from external stimulus-driven toward internal-driven in-
formation processing and therefore may be a determining factor
for the formation of visual hallucinations. In line with this view,
several computational models postulate that an increase in the
excitability of the visual network in the absence of visual input
destabilizes spontaneous neuronal activity, which results in the
formation of elementary visual hallucinations (Ermentrout and
Cowan, 1979; Bressloff et al., 2002; Gutkin et al., 2003; Butler et
al., 2012) that resemble the visual hallucinations produced by
classic hallucinogens (Klu¨ver, 1966; Siegel et al., 1975). In addi-
tion, increased stimulus-independent excitability that is associ-
ated with low  power values is implicated in TMS-induced
phosphenes because the likelihood of experiencing these percepts
is higher during low  power values relative to high  power
values (Romei et al., 2008b). Psilocybin both strongly increased
excitability in the absence of externally presented stimuli by de-
creasing  power values and robustly induced elementary hallu-
cinations in almost all of the subjects. Together, these results
suggest that these  effects may be involved in the formation of
visual hallucinations. However, the correlation between the
psilocybin-induced decrease in  power values and the subject-
reported intensity of visual hallucinations did not reach statistical
significance, indicating that the  power decrease induced by
psilocybin may not be sufficient to generate a subjectively expe-
rienced visual hallucination.
The strong effects of activation of 5-HT2A receptors on 
power values found in this study are consistent with the known
anatomical and functional properties of 5-HT2A receptors in the
visual cortex of animals. The 5-HT2A receptors in the visual cor-
tex are primarily expressed in layers IV-VI (Watakabe et al., 2009;
Moreau et al., 2010), which are crucially implicated in the gener-
ation of  rhythms (Steriade et al., 1990; Bollimunta et al., 2008,
2011). Furthermore, activation of 5-HT2A receptors in the visual
cortex alters the excitatory-inhibitory balance toward excitation
of neurons in layer V (Moreau et al., 2010). Excitatory synaptic
inputs in layer V modulate  oscillations (Jones et al., 2000; Sun
and Dan, 2009), which suggests that 5-HT2A receptor-induced
excitatory effects observed in previous animal studies in layer V
are closely associated with the modulation of  oscillations. Fi-
nally, assuming that the presentation of external stimuli predom-
inantly increases the firing rate of visual neurons from their
prestimulus level (Quiroga et al., 2005;Montemurro et al., 2008),
the opposing effects of 5-HT2A receptors on the excitability dur-
ing the absence of sensory stimuli and in response to sensory
stimuli are consistent with both the suppression effects of
5-HT2A receptor activation on visual neurons with high firing
rates and the facilitation effects on neurons with low firing rate
(Watakabe et al., 2009).
In addition to the profound effects of activation of 5-HT2A
receptors on  oscillations, we also found that activation of
5-HT2A receptors strongly modulated the visual cortex response
that is indexed by visual-evoked P1 and N170 potentials. Specif-
ically, psilocybin increased the medial P1 potential, and the pref-
erential 5-HT2A receptor antagonist ketanserin decreased the P1
potential at the same electrode sites. These results suggest oppos-
ing influences of 5-HT2A agonism and antagonism onmedial P1
potentials. Furthermore, these opposing effects seem to be asso-
ciated with either  power values or phase locking, which sup-
Figure4. Effects of psilocybinandketanserinon thephase-locking index for the threeparieto-occipital ROIs. Placeboplacebo (black), placebopsilocybin (red), ketanserinplacebo (blue),
and ketanserin psilocybin (green).
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ports previous findings that P1 potentials are related to 
oscillations (Gruber et al., 2005; Fellinger et al., 2011; Klimesch,
2011; Rajagovindan and Ding, 2011). Specifically, the individual
decrease in parieto-occipital prestimulus  power by psilocybin
was significantly correlated with the psilocybin-induced increase
in medial P1 potentials in this study. Assuming that the initial
visual gain is modulated by parieto-occipital prestimulus 
power values (Rajagovindan and Ding, 2011) and that the
psilocybin-induced increase in medial P1 potential reflects in-
creased activity in early visual structures (Kometer et al., 2011),
the psilocybin-induced increase in prestimulus excitability may
have amplified the initial visual gain in early visual areas. By
contrast, the decrease in themedial P1 that was observed after the
administration of the 5-HT2A antagonist ketanserin was associ-
ated with a concomitant decrease in  phase locking, which was
most pronounced over the medial parieto-occipital ROI. This
result supports the notion that PLI and P1 potentials are closely
associated (Gruber et al., 2005; Fellinger et al., 2011) and that
attenuation of P1 potentials may be driven by 5-HT2A receptor
antagonism-induced disruption of  phase resetting.
In contrast to the increase of the medial P1 potentials by psi-
locybin, the N170 potentials were strongly decreased by psilocy-
bin and were associated with perceptual alterations, including
visual hallucinations and audio-visual synesthesia. Both theN170
potentials and the perceptual alterations were blocked by pre-
treatment with ketanserin. This result not only supports the no-
tion that activation of 5-HT2A rather than 5-HT1A receptors is a
key mechanism underlying psilocybin-induced visual hallucina-
tions and audio-visual synesthesia, but also suggests that the de-
crease in the N170 potentials is a crucial mechanism underlying
5-HT2A receptor-mediated alterations of visual perceptions.
This mechanism could also constitute a target for the treatment
of visual hallucinations in schizophrenia and Parkinson’s Dis-
ease, because visual hallucinations in these disorders are associ-
ated with altered 5-HT2A receptor expression (Gonza´lez-Maeso
et al., 2008; Ballanger et al., 2010; Huot et al., 2010) and are
effectively treated by compounds that antagonize 5-HT2A recep-
tors (Meltzer et al., 2010). In line with this view, schizophrenic
patients that experience visual hallucinations show not only in-
creased 5-HT2A receptor densities (Gonza´lez-Maeso et al., 2008)
but also attenuated N170 potentials in response to visual stimuli
(Spencer et al., 2004). Accordingly, it is conceivable that the nor-
malization of N170 potentials, which was linked to 5-HT2A an-
tagonism and associated with the disappearance of visual
hallucinations in the present study, may critically contribute to
the therapeutic effect of 5-HT2a antagonists such as atypical
antipsychotics.
The decrease of N170 potentials by 5-HT2A receptor activa-
tion might be associated with visual perceptual distortions be-
cause N170 potentials are crucial for perceiving coherent and
meaningful structures in natural images. Natural visual scenes
often provide ambiguous and incomplete retinal information
about objects; therefore, perceptual organization mechanisms
are required for integrating local edge information into complex
object representations and for interpolating missing parts of ob-
jects. These visual organization processes are associated with
N170 potentials (Herrmann and Bosch, 2001; Murray et al.,
2002), which are localized to the 5-HT2A receptor-rich LOC and
V2 visual areas (Murray et al., 2002; Kometer et al., 2011; Savli et
al., 2012). Thus, 5-HT2A receptor activation within the LOC and
V2 visual area is likely to decrease N170 potentials, leading to
incoherent object representation and arbitrary filling-in pro-
cesses. On the one hand, these processes may be additionally
aggravated by the 5-HT2A receptor-mediated increase in
stimulus-independent excitability of the visual network observed
in this study, which would in turn lead to the formation of spon-
taneous patterns that compete for neuronal representation. On
the other hand, the activation of 5-HT2A receptors decreases
attentional resources (Kometer et al., 2012; Quednow et al.,
2012), which are crucial for visual organization processes (Zhang
and von der Heydt, 2010; Zaretskaya et al., 2013). Therefore,
further studies should address how these two interacting mecha-
nisms contribute to the 5-HT2A receptor-mediated decrease of
N170 potentials.
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